Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

CASI Pharmaceuticals, Inc.2 sites in 1 countryStarted: November 15, 2002Last updated: January 9, 2009

Conditions

Drugs

Trial Snapshot

Phase: Phase 2
Status: Completed
Sponsor: CASI Pharmaceuticals, Inc.
Locations: 2

Study Overview Study Design Eligibility Criteria Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.

Study Design

Study Type: Interventional
Primary Purpose: Treatment

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Investigators

Sponsor

CASI Pharmaceuticals, Inc.

Sponsor Class

Industry

Study Sites (2)

Loading locations...

Similar Trials

Terminated

Phase 1

rhEndostatin Protein Involving Pediatric Patients With CancerSolid Tumors

NCT00165373Dana-Farber Cancer Institute21

Completed

Phase 4

Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic PatientsType IIa and IIb Hypercholesterolaemia

NCT00631189AstraZeneca668

Unknown

Phase 2

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLCStaging IV NSCLC

NCT04094909Guangzhou Institute of Respiratory Disease186

Unknown

Phase 4

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) StudyStage D Heart Failure

NCT04191681The Cleveland Clinic50

Completed

Phase 3

The Effects of Atorvastatin in Patients With AtherosclerosisAtherosclerosis

NCT00115817Brigham and Women's Hospital36